Search Results | NIH

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Search Results 21 – 40 of 3231

Table A. Summary of IMPAACT P1066 Cohorts and Participation

https://clinicalinfo.hiv.gov/table/table-summary-impaact-p1066-cohorts-and-participation

Table B. Raltegravir Pharmacokinetic Parameters for Raltegravir-Naive and Raltegravir-Exposed Neonates

https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/raltegravir-full

Table 17a. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Central Nervous System Toxicity

https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/cns-toxicity-full

Table 17b. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Dyslipidemia

https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/dyslipidemia-full

Table 17c. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Gastrointestinal Effects

https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/gastrointestinal-effects-full

Table 17d. Antiretroviral Therapy-Associated Adverse Effects and Management Recommendations—Hematologic Effects

https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/hematologic-effects-full

Table 17e. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Hepatic Events

https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/hepatic-events-full

Table 17f. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Insulin Resistance, Asymptomatic Hyperglycemia, and Diabetes Mellitus

https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/insulin-resistance-asymptomatic-hyperglycemia-diabetes-mellitus-full

Table 17g. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Lactic Acidosis

https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/lactic-acidosis-full

Table 17h. Antiretroviral Therapy-Associated Adverse Effects and Management Recommendations—Lipodystrophies and Weight Gain

https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/lipodystrophies-and-weight-gain-full

Table 17i. Antiretroviral Therapy-Associated Adverse Effects and Management Recommendations—Nephrotoxic Effects

https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/nephrotoxic-effects-full

Table 17j. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Osteopenia and Osteoporosis

https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/osteopenia-and-osteoporosis-full

Table 17k. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Rash and Hypersensitivity Reactions

https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/rash-and-hypersensitivity-reactions-full

Appendix A, Table 1. Antiretrovirals Available in Fixed-Dose Combination Tablets or as a Co-packaged Formulation, by Drug Class

https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/appendix-table-1-antiretrovirals-available-fixed-dose-combination-tablets-full

Fostemsavir (Rukobia, FTR)

https://clinicalinfo.hiv.gov/guidelines/perinatal/safety-toxicity-arv-agents-entry-attachment-inhibitors-fostemsavir-rukobia

Table 7. Situation-Specific Recommendations for Use of Antiretroviral Drugs During Pregnancy and When Trying to Conceive

https://clinicalinfo.hiv.gov/guidelines/perinatal/recommendations-arv-drugs-pregnancy-situation-specific-conceive-full

Pre-exposure Prophylaxis (PrEP) to Prevent HIV During Periconception, Antepartum, and Postpartum Periods

https://clinicalinfo.hiv.gov/guidelines/perinatal/pre-exposure-prophylaxis-prep-prevent-hiv

https://clinicalinfo.hiv.gov/drugs/cabotegravir-1/patient

https://clinicalinfo.hiv.gov/drugs/cabotegravir-1/patient

https://clinicalinfo.hiv.gov/drugs/cabotegravir-1/fda-label